NAUT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 28, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results and Platform Progress

Oct 26, 2026

8-K

Nautilus Biotechnology Enters into $125 Million "At the Market" Sales Agreement and Terminates Prior Agreement

Sep 11, 2026

8-K

Nautilus Biotechnology Reports Q2 2026 Financial Results and Strategic Roadmap Realignment

Jul 27, 2026

8-K

Nautilus Biotechnology, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Nautilus Biotechnology Reports First Quarter 2026 Financial Results

Apr 27, 2026

8-K

Nautilus Biotechnology Reports Q4 and FY 2025 Financial Results and Provides 2026 Outlook

Feb 25, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* September 2026 ATM | Offering amount: $125,000,000 | Bank: TD Cowen

Sep 18, 2026

424B5

ATM | Offering amount: $125,000,000

Mar 6, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 88,738,387

Nov 21, 2023

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 88,738,387

Aug 9, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 95,645,056

Aug 2, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 95,645,056

Jun 16, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-3

September 2026 SHELF + ATM

Sep 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2025

S-3

SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE

Feb 28, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 23, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

PERCEPTIVE ADVISORS LLC (Filed by)

Nov 3, 2026

SCHEDULE 13D/A

AH Bio Fund II, L.P. (Filed by)

Sep 11, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Sep 11, 2026

SCHEDULE 13D/A

AH Bio Fund II, L.P. (Filed by)

Aug 28, 2026

SCHEDULE 13D/A

PERCEPTIVE ADVISORS LLC (Filed by)

Aug 14, 2026

SCHEDULE 13D/A

AH Bio Fund II, L.P. (Filed by)

Jun 30, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 21, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 7, 2024

CORRESP

Form CORRESP - Correspondence

Mar 4, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 4, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 9, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 2, 2022

Nautilus Biotechnolgy, Inc. NAUT · SEC Filings